AMGEN INC — Director's Dealing 2021

Mar 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2021-03-02

Reporting Person: Grygiel Nancy A. (SVP & CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	A	1245	—	Acquired	12401	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	89.9976	Indirect

Footnotes

F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; and 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 185 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F3: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.